Acute Treatment Patterns, Migraine Burden, and Healthcare Resource Use in People With Migraine: Results From the OVERCOME (EU) Observational Study.
Acute treatment patterns
Burden of migraine
Migraine
Migraine symptoms
Severe headache
Treatment satisfaction
Journal
Pain and therapy
ISSN: 2193-8237
Titre abrégé: Pain Ther
Pays: New Zealand
ID NLM: 101634491
Informations de publication
Date de publication:
16 Apr 2024
16 Apr 2024
Historique:
received:
06
12
2023
accepted:
22
02
2024
medline:
16
4
2024
pubmed:
16
4
2024
entrez:
16
4
2024
Statut:
aheadofprint
Résumé
The ObserVational survey of the Epidemiology, tReatment and Care Of MigrainE (OVERCOME) European Union (EU) is part of an overarching population-based study program that also includes the United States and Japan. Here, we report data on the migraine/severe headache burden and the use of acute medication and healthcare resources in Spain and Germany. OVERCOME (EU) was an online, non-interventional, cross-sectional survey conducted in adults in Spain and Germany between October 2020 and February 2021. A total migraine cohort was established based on health survey participants who reported headache/migraine in the last 12 months AND identified as having migraine based on modified International Classification of Headache Disorders, third edition criteria OR self-reported physician diagnosis. Data were analyzed for the total migraine cohort and the subcohort with moderate to severe headache attacks, with average pain severity ≥ 5 points, pain duration ≥ 4 h, and at least moderate disability due to migraine [Migraine Disability Assessment (MIDAS) score ≥ 11] over the past 3 months. Pain of moderate or severe intensity was the most frequent symptom in the total migraine cohort (n = 19,103/20,756; 92.0%). Proportions of participants reporting severe disability (MIDAS Grade IV), poorer quality of life (QoL; Migraine-Specific QoL Questionnaire), and higher interictal burden (Migraine Interictal Burden Scale-4), generally increased with number of headache days (HDs)/month. Most participants (92.5%) reported current acute migraine/severe headache medication use, although only 39.0% were using triptans. In the moderate to severe attacks subcohort (n = 5547), 48.4% were using triptans, with nonsteroidal anti-inflammatory drugs the most common acute medication. The moderate to severe attacks subcohort also reported poorer QoL and greater pain and disability with increasing HDs/month, although severe interictal burden was reported for ~ 60% of participants regardless of HDs/month. Treatment satisfaction (six-item migraine Treatment Optimization Questionnaire) in those using triptans was generally poor in both total and subcohorts. High migraine-related burden levels were reported, despite use of acute medication. Although triptans are recommended for moderate to severe migraine attacks in Spanish and German guidelines, less than half of participants were using triptans; treatment satisfaction in those using triptans was generally poor. New tailored treatment options may help address unmet needs in current acute treatment.
Identifiants
pubmed: 38625512
doi: 10.1007/s40122-024-00589-3
pii: 10.1007/s40122-024-00589-3
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight project. J Headache Pain. 2010;11(4):289–99. https://doi.org/10.1007/s10194-010-0217-0 .
doi: 10.1007/s10194-010-0217-0
pubmed: 20473702
pmcid: 2917556
Matías-Guiu J, Porta-Etessam J, Mateos V, et al. One-year prevalence of migraine in Spain: a nationwide population-based survey. Cephalalgia. 2011;31(4):463–70. https://doi.org/10.1177/0333102410382794 .
doi: 10.1177/0333102410382794
pubmed: 20819843
Yoon M-S, Katsarava Z, Obermann M, et al. Prevalence of primary headaches in Germany: results of the German Headache Consortium Study. J Headache Pain. 2012;13(3):215–23. https://doi.org/10.1007/s10194-012-0425-x .
doi: 10.1007/s10194-012-0425-x
pubmed: 22395638
pmcid: 3311829
Salazar A, Berrocal L, Failde I. Prevalence of migraine in general Spanish population; factors related and use of health resources. Int J Environ Res Public Health. 2021;18(21):11145. https://doi.org/10.3390/ijerph182111145 .
doi: 10.3390/ijerph182111145
pubmed: 34769668
pmcid: 8583596
Roessler T, Zschocke J, Roehrig A, Friedrichs M, Friedel H, Katsarava Z. Administrative prevalence and incidence, characteristics and prescription patterns of patients with migraine in Germany: a retrospective claims data analysis. J Headache Pain. 2020;21(1):85. https://doi.org/10.1186/s10194-020-01154-x .
doi: 10.1186/s10194-020-01154-x
pubmed: 32631274
pmcid: 7339552
Feigin VL, Nichols E, Alam T, et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459–80. https://doi.org/10.1016/S1474-4422(18)30499-X .
doi: 10.1016/S1474-4422(18)30499-X
Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z, Lifting The Burden: the Global Campaign against Headache. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137. https://doi.org/10.1186/s10194-020-01208-0 .
doi: 10.1186/s10194-020-01208-0
pubmed: 33267788
pmcid: 7708887
Ferracini GN, Dach F, Speciali JG. Quality of life and health-related disability in children with migraine. Headache. 2014;54(2):325–34. https://doi.org/10.1111/head.12251 .
doi: 10.1111/head.12251
pubmed: 24512577
Insinga RP, Ng-Mak DS, Hanson ME. Costs associated with outpatient, emergency room and inpatient care for migraine in the USA. Cephalalgia. 2011;31(15):1570–5. https://doi.org/10.1177/0333102411425960 .
doi: 10.1177/0333102411425960
pubmed: 22013140
Lipton RB, Buse DC, Saiers J, Serrano D, Reed ML. Healthcare resource utilization and direct costs associated with frequent nausea in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. J Med Econ. 2013;16(4):490–9. https://doi.org/10.3111/13696998.2013.770748 .
doi: 10.3111/13696998.2013.770748
pubmed: 23356422
Diener H-C, Holle D, Dresler T, Gaul C. Chronic headache due to overuse of analgesics and anti-migraine agents. Dtsch Arztebl Int. 2018;115(22):365–70. https://doi.org/10.3238/arztebl.2018.0365 .
doi: 10.3238/arztebl.2018.0365
pubmed: 29932046
pmcid: 6039717
Buse DC, Rupnow MFT, Lipton RB. Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc. 2009;84(5):422–35. https://doi.org/10.1016/S0025-6196(11)60561-2 .
doi: 10.1016/S0025-6196(11)60561-2
pubmed: 19411439
pmcid: 2676125
Linde M, Gustavsson A, Stovner LJ, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012;19(5):703–11. https://doi.org/10.1111/j.1468-1331.2011.03612.x .
doi: 10.1111/j.1468-1331.2011.03612.x
pubmed: 22136117
Parikh SK, Young WB. Migraine: stigma in society. Curr Pain Headache Rep. 2019;23(1):8. https://doi.org/10.1007/s11916-019-0743-7 .
doi: 10.1007/s11916-019-0743-7
pubmed: 30739216
Agosti R. Migraine burden of disease: from the patient’s experience to a socio-economic view. Headache. 2018;58:17–32. https://doi.org/10.1111/head.13301 .
doi: 10.1111/head.13301
pubmed: 29697152
Sokolovic E, Riederer F, Szucs T, Agosti R, Sándor PS. Self-reported headache among the employees of a Swiss university hospital: prevalence, disability, current treatment, and economic impact. J Headache Pain. 2013;14(1):29. https://doi.org/10.1186/1129-2377-14-29 .
doi: 10.1186/1129-2377-14-29
pubmed: 23565579
pmcid: 3639129
Lasaosa SS, Rosich PR, editors. Manual de práctica clínica en cefaleas: recomendaciones diagnóstico-terapéuticas de la Sociedad Española de Neurología en 2020. Madrid: Sociedad Española de Neurología. 2020. p. 1–476. http://cefaleas.sen.es/pdf/ManualCefaleas2020.pdf . Accessed 15 Nov 2023.
Diener H-C, Holle-Lee D, Nägel S, et al. Treatment of migraine attacks and prevention of migraine: guidelines by the German Migraine and Headache Society and the German Society of Neurology. Clin Transl Neurosci. 2019;3(1):1–40. https://doi.org/10.1177/2514183X18823377 .
doi: 10.1177/2514183X18823377
Katsavara Z, Mania M, Lampl C, Herberhold J, Steiner TJ. Poor medical care for people with migraine in Europe—evidence from the Eurolight study. J Headache Pain. 2018;19(1):10. https://doi.org/10.1186/s10194-018-0839-1 .
doi: 10.1186/s10194-018-0839-1
Lipton RB, Nicholson RA, Reed ML, et al. Diagnosis, consultation, treatment, and impact of migraine in the US: results of the OVERCOME (US) study. Headache. 2022;62(2):122–40. https://doi.org/10.1111/head.14259 .
doi: 10.1111/head.14259
pubmed: 35076091
pmcid: 9305407
Matsumori Y, Ueda K, Komori M, et al. Burden of migraine in Japan: results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) Study. Neurol Ther. 2022;11(1):205–22. https://doi.org/10.1007/s40120-021-00305-9 .
doi: 10.1007/s40120-021-00305-9
pubmed: 34862581
Hirata K, Ueda K, Komori M, et al. Comprehensive population-based survey of migraine in Japan: results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study. Curr Med Res Opin. 2021;37(11):1945–55. https://doi.org/10.1080/03007995.2021.1971179 .
doi: 10.1080/03007995.2021.1971179
pubmed: 34429000
Pascual J, Panni T, Dell’Agnello G, Gonderten S, Novick D, Evers S. Preventive treatment patterns and treatment satisfaction in migraine: results from the OVERCOME (EU) study. J Headache Pain. 2023;24(1):88. https://doi.org/10.1186/s10194-023-01623-z .
doi: 10.1186/s10194-023-01623-z
pubmed: 37460942
pmcid: 10351193
Gupta S, Ryvlin P, Faught E, Tsong W, Kwan P. Understanding the burden of focal epilepsy as a function of seizure frequency in the United States, Europe, and Brazil. Epilepsia Open. 2017;2(2):199–213. https://doi.org/10.1002/epi4.12050 .
doi: 10.1002/epi4.12050
pubmed: 29588949
pmcid: 5719850
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. https://doi.org/10.1177/0333102417738202 .
Stewart WF, Lipton RB, Kolodner K, Liberman J, Sawyer J. Reliability of the Migraine Disability Assessment score in a population-based sample of headache sufferers. Cephalalgia. 1999;19(2):107–14. https://doi.org/10.1046/j.1468-2982.1999.019002107.x .
doi: 10.1046/j.1468-2982.1999.019002107.x
pubmed: 10214536
Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain. 2000;88(1):41–52. https://doi.org/10.1016/S0304-3959(00)00305-5 .
doi: 10.1016/S0304-3959(00)00305-5
pubmed: 11098098
Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001;56(6 Suppl 1):S20–8. https://doi.org/10.1212/wnl.56.suppl_1.s20 .
doi: 10.1212/wnl.56.suppl_1.s20
pubmed: 11294956
Lipton RB, Serrano D, Nicholson RA, Buse DC, Runken MC, Reed ML. Impact of NSAID and triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013;53(10):1548–63. https://doi.org/10.1111/head.12201 .
doi: 10.1111/head.12201
pubmed: 23992516
Adams AM, Serrano D, Buse DC, et al. The impact of chronic migraine: the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia. 2015;35(7):563–78. https://doi.org/10.1177/0333102414552532 .
doi: 10.1177/0333102414552532
pubmed: 25304766
pmcid: 4430584
Rodríguez-Almagro D, Achalandabaso A, Rus A, Obrero-Gaitán E, Zagalaz-Anula N, Lomas-Vega R. Validation of the Spanish version of the Migraine Disability Assessment Questionnaire (MIDAS) in university students with migraine. BMC Neurol. 2020;20(1):67. https://doi.org/10.1186/s12883-020-01646-y .
doi: 10.1186/s12883-020-01646-y
pubmed: 32093620
pmcid: 7038557
Benz T, Lehmann S, Gantenbein AR, et al. Translation, cross-cultural adaptation and reliability of the German version of the migraine disability assessment (MIDAS) questionnaire. Health Qual Life Outcomes. 2018;16(1):42. https://doi.org/10.1186/s12955-018-0871-5 .
doi: 10.1186/s12955-018-0871-5
pubmed: 29523138
pmcid: 5845367
Lipton RB, Fanning KM, Serrano D, Reed ML, Cady R, Buse DC. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology. 2015;84(7):688–95. https://doi.org/10.1212/WNL.0000000000001256 .
doi: 10.1212/WNL.0000000000001256
pubmed: 25609757
pmcid: 4336107
Lipton RB, Kolodner K, Bigal ME, et al. Validity and reliability of the migraine-treatment optimization questionnaire. Cephalalgia. 2009;29(7):751–9. https://doi.org/10.1111/j.1468-2982.2008.01786.x .
doi: 10.1111/j.1468-2982.2008.01786.x
pubmed: 19239676
Jhingran P, Osterhaus JT, Miller DW, Lee JT, Kirchdoerfer L. Development and validation of the Migraine-Specific Quality of Life Questionnaire. Headache. 1998;38(4):295–302. https://doi.org/10.1046/j.1526-4610.1998.3804295.x .
doi: 10.1046/j.1526-4610.1998.3804295.x
pubmed: 9595870
Jhingran P, Davis SM, LaVange LM, Miller DW, Helms RW. MSQ: Migraine-Specific Quality-of-Life Questionnaire: further investigation of the factor structure. Pharmacoeconomics. 1998;13(6):707–17. https://doi.org/10.2165/00019053-199813060-00007 .
doi: 10.2165/00019053-199813060-00007
pubmed: 10179706
Buse D, Bigal MB, Rupnow M, Reed M, Serrano D, Lipton R. Development and validation of the Migraine Interictal Burden Scale (MIBS): a self-administered instrument for measuring the burden of migraine between attacks. Neurology. 2007;68:A89.
Zebenholzer K, Gall W, Wöber C. Use and overuse of triptans in Austria—a survey based on nationwide healthcare claims data. J Headache Pain. 2018;19(1):34. https://doi.org/10.1186/s10194-018-0864-0 .
doi: 10.1186/s10194-018-0864-0
pubmed: 29777424
pmcid: 5959824
Lombard L, Farrar M, Ye W, et al. A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication. J Headache Pain. 2020;21(1):41. https://doi.org/10.1186/s10194-020-01110-9 .
doi: 10.1186/s10194-020-01110-9
pubmed: 32349662
pmcid: 7189443
Viana M, Genazzani AA, Terrazzino S, Nappi G, Goadsby PJ. Triptan nonresponders: do they exist and who are they? Cephalalgia. 2013;33(11):891–6. https://doi.org/10.1177/0333102413480756 .
doi: 10.1177/0333102413480756
pubmed: 23564209
Leroux E, Buchanan A, Lombard L, et al. Evaluation of patients with insufficient efficacy and/or tolerability to triptans for the acute treatment of migraine: a systematic literature review. Adv Ther. 2020;37(12):4765–96. https://doi.org/10.1007/s12325-020-01494-9 .
doi: 10.1007/s12325-020-01494-9
pubmed: 32990921
pmcid: 7595976
Buse DC, Serrano D, Kori S, et al. Consistency vs. switching triptan treatment and headache-related disability: results of the American migraine prevalence & prevention study. J Headache Pain. 2013;14(Suppl 1):P212. https://doi.org/10.1186/1129-2377-1-S14-P212 .
doi: 10.1186/1129-2377-1-S14-P212
pmcid: 3620311